Pfizer Inc. expects to manufacture 80 million treatments of its experimental antiviral drug for COVID-19, up from a previous forecast of 50 million, announced its CEO Albert Bourla.
Earlier this month, Pfizer said it expects to make 180,000 treatments by the end of this year and at least 50 million by the end of next year, including 21 million in the first half of 2022.
“Right now we can commit to 80 million doses“Bourla said in an interview with CNBC.
He stressed that he is confident that the pill – named Paxlovid – would not be affected by the omicron variant of the coronavirus and that the company would know more details about the new strain in the coming weeks.
Pfizer It applied for emergency authorization from Paxlovid last week after submitting data showing it was 89% effective in preventing hospitalization or death in people at risk.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
